A key national pro-life group has accused the U.S. Department of Justice of undermining Louisiana’s efforts to roll back the Biden administration‘s eased restrictions on mifepristone when the Justice Department asked a court to pause the Pelican State’s challenge to that policy. In a Jan. 27 court filing, DOJ lawyers said a safety review of mifepristone is underway, and that such studies often take about one year. The plaintiff’s request to end mail-order distribution of the drug, the filing said, “may prove as unnecessary as it is disruptive, if FDA ultimately decides that the in-person dispensing requirement must be restored.” More than six of 10 abortions in the U.S. are performed through a combination of mifepristone and misoprostol, according to recent estimates.
